TTrialPathMatch Me to Trials
← Back to trials
RecruitingOvarian CancerFallopian TubePrimary Peritoneal Cancer

Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Eligible age

18+ yrs

Accepts

Women

Locations

8 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The proposed study design is a single arm Phase II trial to document the feasibility of carboplatin-mirvetuximab - in patients with advanced-stage EOC. Patients with biopsy confirmed, newly diagnosed, advanced-stage serous EOC deemed appropriate for NACT will have their tumors evaluated for FRα receptor over-expression via a centralized immunohistochemical assay (IHC) and identified as appropriate for study participation if IHC staining is PS2+ in \>75% of cells (40% of all serous patients). Eligible patients will receive NACT with one cycle of carboplatin, followed by mirvetuximab + carboplatin (if FRα +) every 21 days for three cycles prior to interval cytoreductive surgery (iCRS). A total of 70 will be included in the study. Following completion of 4 cycles total of NACT and after allowing for appropriate recovery of cycle # 4, patients eligible for surgery, will undergo an iCRS. Patients will then complete 3 more cycles of mirvetuximab + carboplatin for a total of 7 intended cycles of treatment. It is up to the treating physician if they want to add bevacizumab to the last 2 cycles or use any type of maintenance therapy. The decision to add bevacizumab or use maintenance therapy does not need to be made upfront. Patients will sign a screening consent form prior to tissue biopsy. If a patient is found to be FRα negative, their treating physician can select the treatment they deem appropriate and the patient will be declared a screen failure. Patients with BRCA mutations are not excluded from this trial and are allowed to receive standard of care maintenance therapy including bevacizumab and/or PARP inhibitors.

Sponsor: University of Alabama at Birmingham

You may qualify if…

  • ✓ Patients must have biopsy-confirmed high grade serous epithelial ovarian cancer.
  • ✓ Patients must present with stage III or IV disease and be appropriate to receive neoadjuvant chemotherapy
  • ✓ Patients must be willing to provide an archival tumor tissue block or slides, or undergo procedure to obtain a new biopsy using a low-risk, medically routine procedure for immunohistochemistry (IHC) confirmation of FRα positivity
  • ✓ Patients must have a performance status of 0 or 1.
  • ✓ Patient's tumor must be positive for FRα expression as defined by a score of PS2+ intensity in \>75% of cells
  • ✓ Patients must have adequate hematologic, liver and kidney functions defined as:
  • ✓ Absolute neutrophil count (ANC) ≥ 1.5 x 109/L (1,500/μL)
  • ✓ Platelet count ≥ 100 x 109/L (100,000/μL) without platelet transfusion in the prior 10 days

You may not qualify if…

  • ✕ Patients who have previously been treated with a systemic anti-cancer therapy
  • ✕ Patients with low-grade serous, endometrioid, clear cell, or mucinous histology
  • ✕ Patients with active or chronic corneal disorders, history of corneal transplantation, or active ocular conditions requiring ongoing treatment/monitoring, such as uncontrolled glaucoma, wet age-related macular degeneration requiring intravitreal injections, active diabetic retinopathy with macular edema, macular degeneration, presence of papilledema, and /or monocular vision
  • ✕ Patients with serious concurrent illness or clinically relevant active infection, including, but not limited to the following:
  • ✕ History of hepatitis B or C infection (whether or not on active antiviral therapy)
  • ✕ History of human immunodeficiency virus (HIV) infection
  • ✕ Any other concurrent infectious disease requiring IV antibiotics within 2 weeks prior to the first dose of MIRV
  • ✕ Patients with a history of multiple sclerosis (MS) or other demyelinating disease and/or Lambert-Eaton syndrome (paraneoplastic syndrome)

Where it's recruiting

Alabama

Birmingham

California

San Francisco

Minnesota

Minneapolis · Rochester

Ohio

Columbus

Oklahoma

Oklahoma City

Pennsylvania

Pittsburgh

Virginia

Richmond

Source: ClinicalTrials.gov · NCT04606914 · last updated 2026-07-14